FIG. 4.
Long-term protection against L.m.-OVA infection. (a) Experimental protocol: C57BL/6 mice were vaccinated with pcDNA3-OVA, T0H-OVA, or T0-GFP (4 × 106 virus particles i.v.) and infected i.v. with 5 × 104 (two times the LD50) L.m.-OVA cells 6 weeks later. (b) The percentage of H-2Kb/OVA257-264 tetramer-specific cells among CD8+ T lymphocytes in the blood was determined by flow cytometry at the days indicated. (c) Survival of the mice was monitored daily; no death occurred after day 7 postinfection. (d) On day 7 after infection (day 49 postvaccination), spleen, mesenteric (mes), inguinal, and brachial lymph nodes were isolated and analyzed by flow cytometry; inguinal and brachial lymph nodes (ing. and bra. LN) were pooled for each mouse. The bar graphs depict the percentage (mean ± standard deviation [error bars]) of H-2Kb/OVA257-264 tetramer-positive cells among CD8+ T cells (n = 4 to 5 per group).